Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosome–positive acute lymphoblastic leukemia
Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Rebecca Garris(The University of Texas MD Anderson Cancer Center), Stefan Faderl(Jazz Pharmaceuticals (United States)), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Deborah Thomas, Xuelin Huang(The University of Texas MD Anderson Cancer Center), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Srđan Verstovšek(Unknown), Deborah McCue(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Susan O’Brien(University of California, Irvine), Michael Rytting(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health)
Cited by 227
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k